ÈËÆÞÖгöÊÓƵ

Ami B. Patel
( out of 47 reviews )

Ami B. Patel, MD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Salt Lake City
801-585-2626

  • Dr. Ami Patel is an Assistant Professor of Medicine within the Division of Hematology and Hematologic Malignancies at the Huntsman Cancer Institute/ÈËÆÞÖгöÊÓƵ of Utah. She is a hematologist and physician-scientist with an NIH-funded independent translational research program investigating the biology of myeloid malignancies, specifically myeloid leukemogenesis as it relates to the intersection of inflammation, aging and oncogenic kinase signaling. Her clinical practice encompasses the diagnosis and treatment of myelodysplastic/myeloproliferative (MDS/MPN) overlap disorders, myeloproliferative neoplasms (MPNs), and acute myeloid leukemia (AML). Dr. Patel's research focuses on understanding cell signaling in myeloid leukemias and the molecular mechanisms governing drug resistance to targeted agents in these diseases. Her laboratory-based research complements her clinical practice by informing novel treatment strategies for implementation in early-phase clinical trials - with the goal of rapidly translating relevant preclinical findings and improving outcomes for leukemia patients. Dr. Patel's laboratory has specific expertise in studying resistance mechanisms to kinase inhibitors that act upon oncogenic kinases such as MEK1/2, BCR-ABL1, JAK2 and FLT3-ITD. Previously, she found that resistance to the FLT3 inhibitor quizartinib is mediated through soluble factors secreted by bone marrow stromal cells in AML (Patel et al, Leukemia, 2020). Dr. Patel has led the effort to functionally characterize a novel JAK2 insertion-deletion mutant associated with resistance to JAK2 inhibition and clinical features of both polycythemia and hypereosinophilia (Patel et al, Blood, 2019). She is the principal investigator on an investigator-initiated trial (NCT04409639) of the MEK inhibitor cobimetinib in RAS/MAPK-activated chronic myelomonocytic leukemia (CMML) that will help define the efficacy of RAS/MAPK inhibition in this disease and elucidate mechanisms of resistance to oncogenic RAS/MAPK signaling in myeloid leukemias.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    5.0 /5
    ( out of 47 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    November 04, 2024
    HUNTSMAN CANCER CENTER

    Dr. Patel was excellent! She took time with us to make sure we understood all the aspected if my diagnosis and treatment and answer the many questions we had. She has a great doctor / patient bedside manner and was very knowledgeable. She explored new research treatment options and shared details and the advantages and disadvantages of each treatment. You can tell she is passionate about her calling in medicine. She was professional and warm. It was a very reassuring experience for me in going forward with my treatment at Huntsman.

    October 19, 2024
    HUNTSMAN CANCER CENTER

    Dr. Patel is one of the finest MD's I've every had. She is wonderful!

    October 04, 2024
    HUNTSMAN CANCER CENTER

    Very thorough and compassionate

    September 26, 2024
    HUNTSMAN CANCER CENTER

    Doctor Patel is an excellent doctor.

    September 16, 2024
    HUNTSMAN CANCER CENTER

    Dr Ami B Patel, MD, has been my oncologist for just shy of five years. She is very friendly, kind, caring and gentle. She always greets me with a wonderful smile and makes me feel so comfortable. Dr Patel listens and explains things so I understand. She obviously cares about me and my health journey. I'm so grateful to have Dr Patel as my oncologist.

    July 27, 2024
    HUNTSMAN CANCER CENTER

    Very good knowledge on CMML.

    July 26, 2024
    HUNTSMAN CANCER CENTER

    Excellent hermatogist would recommend to friends and family very responsive and knowledgeable about CMML

    July 03, 2024
    HUNTSMAN CANCER CENTER

    Dr. Patel is a wonderful doctor. She truly cares about her patients as individuals and anticipates their needs. She is amazing at explaining things and taking time to ensure patient understanding. She is truly a gift to her hematology practice. Her staff is equally amazing!

    June 14, 2024
    HUNTSMAN CANCER CENTER

    Very thorough and compassion care

    See More Patient Comments

  • Dr. Ami Patel is an Assistant Professor of Medicine within the Division of Hematology and Hematologic Malignancies at the Huntsman Cancer Institute/ÈËÆÞÖгöÊÓƵ of Utah. She is a hematologist and physician-scientist with an NIH-funded independent translational research program investigating the biology of myeloid malignancies, specifically myeloid leukemogenesis as it relates to the intersection of inflammation, aging and oncogenic kinase signaling. Her clinical practice encompasses the diagnosis and treatment of myelodysplastic/myeloproliferative (MDS/MPN) overlap disorders, myeloproliferative neoplasms (MPNs), and acute myeloid leukemia (AML). Dr. Patel's research focuses on understanding cell signaling in myeloid leukemias and the molecular mechanisms governing drug resistance to targeted agents in these diseases. Her laboratory-based research complements her clinical practice by informing novel treatment strategies for implementation in early-phase clinical trials - with the goal of rapidly translating relevant preclinical findings and improving outcomes for leukemia patients. Dr. Patel's laboratory has specific expertise in studying resistance mechanisms to kinase inhibitors that act upon oncogenic kinases such as MEK1/2, BCR-ABL1, JAK2 and FLT3-ITD. Previously, she found that resistance to the FLT3 inhibitor quizartinib is mediated through soluble factors secreted by bone marrow stromal cells in AML (Patel et al, Leukemia, 2020). Dr. Patel has led the effort to functionally characterize a novel JAK2 insertion-deletion mutant associated with resistance to JAK2 inhibition and clinical features of both polycythemia and hypereosinophilia (Patel et al, Blood, 2019). She is the principal investigator on an investigator-initiated trial (NCT04409639) of the MEK inhibitor cobimetinib in RAS/MAPK-activated chronic myelomonocytic leukemia (CMML) that will help define the efficacy of RAS/MAPK inhibition in this disease and elucidate mechanisms of resistance to oncogenic RAS/MAPK signaling in myeloid leukemias.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Fellowship Hematology/Oncology Research - ÈËÆÞÖгöÊÓƵ of Utah Advanced Fellow
    Fellowship Hematology/Oncology Fellowship Program - ÈËÆÞÖгöÊÓƵ of Utah School of Medicine Chief Fellow
    Fellowship Hematology/Oncology - ÈËÆÞÖгöÊÓƵ of Utah School of Medicine Fellow
    Residency Internal Medicine - McGaw Medical Center of Northwestern ÈËÆÞÖгöÊÓƵ Resident
    Internship Internal Medicine - McGaw Medical Center of Northwestern ÈËÆÞÖгöÊÓƵ Intern
    Professional Medical Medicine - Northwestern ÈËÆÞÖгöÊÓƵ Feinberg School of Medicine M.D.
    Undergraduate Biology - Northwestern ÈËÆÞÖгöÊÓƵ B.S.

    Selected Publications

    Journal Article

    1. Patel AB, Deininger MW (2020). Genetic complexity of chronic myelomonocytic leukemia. Leuk Lymphoma, 62(5), 1031-1045. ()
    2. Yan D, Franzini A, Pomicter AD, Halverson BJ, Antelope O, Mason CC, Ahmann JM, Senina AV, Vellore NA, Jones CL, Zabriskie MS, Than H, Xiao MJ, van Scoyk A, Patel AB, Clair PM, Heaton WL, Owen SC, Andersen JL, Egbert CM, Reisz JA, DAlessandro A, Cox JE, Gantz KC, Redwine HM, Iyer SM, Khorashad JS, Rajabi N, Olsen CA, OHare T, Deininger MW (2019). SIRT5 IS A DRUGGABLE METABOLIC VULNERABILITY IN ACUTE MYELOID LEUKEMIA. Blood Cancer Discov, 2(3), 266-287. ()
    3. Patel AB, Pomicter AD, Yan D, Eiring AM, Antelope O, Schumacher JA, Kelley TW, Tantravahi SK, Kovacsovics TJ, Shami PJ, OHare T, Deininger MW (2020). Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms. Leukemia, 34(11), 2981-2991. ()
    4. Patel AB, Franzini A, Leroy E, Kim SJ, Pomicter AD, Genet L, Xiao M, Yan D, Ahmann JM, Agarwal AM, Clair P, Addada J, Lambert J, Salmon M, Gleich GJ, Cross NCP, Constantinescu SN, OHare T, Prchal JT, Deininger MW (2019). JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera. Blood, 134(26), 2388-2398. ()
    5. Antelope O, Vellore NA, Pomicter AD, Patel AB, Van Scoyk A, Clair PM, Deininger MW, OHare T (2019). BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia. Exp Hematol, 77, 36-40.e2. ()
    6. Patel AB, Miles RR, Deininger MW (2019). Lysozyme nephropathy in chronic myelomonocytic leukemia. Clin Case Rep, 7(6), 1263-1264. ()
    7. Patel AB, Pettijohn EM, Abedin SM, Raps E, Deininger MW (2019). Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendations. Blood Adv, 3(7), 952-955. ()
    8. Patel AB, Chen YH, Zhang Y, Frankfurt O, Winter JN (2014). Achievement of morphologic and cytogenetic remission with single-agent hydroxyurea in a patient with acute myeloid leukemia with inv(16). Leuk Lymphoma, 56(3), 817-9. ()

  • News & Podcasts

    Huntsman Cancer Institute News

  • Clinical Trials